Internt rum This page in english
KOL i almen praksis
Forord Læsevejledning Indledning Forkortelser og definitioner KOL − en invaliderende sygdom i vækst Kvalitetssikring KOL-definition Årsager til KOL Symptomer KOL og registrering KOL-diagnosticering KOL-klassifikation Undersøgelser på diagnosetidspunktet Differentialdiagnoser Behandlingsstrategi Behandling i stabil fase Behandling af eksacerbation Rygeafvænning KOL og fysisk aktivitet KOL og rehabilitering KOL-patienter og ernæring KOL og comorbiditet Angst og depression KOL og osteoporose KOL og iltbehandling Influenzavaccination Pneumokokvaccination Lungekirurgisk intervention KOL i terminalfasen Udredning, opfølgning og stratificering KOL-årskontrol KOL-stratificering KOL og flyrejse KOL og egenomsorg Patientorganisationer Appendiks B1. Spirometri B2. Normalværdier B3. Fletcher-kurven B4. Rygestopguide B5. Træningsprogram B6. Henvisning B7. KOL-årskontrol B8. Fordeling af opgaver B9. Udstyr B10. LINQ B11. Selvbehandlingsplan B12. Patientvejledning B13. Patient forberedelse B14. Proteinbehov B15. Ydelse 0106 Litteraturliste Interessekonflikter Kolofon
Type 2-diabetes
Blødningsforstyrrelser hos kvinder i almen praksis
Sidst opdateret:
17. apr '08 Kl. 17:20 af ASG
  1. The European health report 2005. Public health action for healthier children and populations. WHO. http://www.euro.who.int/document/e87325.pdf; 2005.
  2. DAK - Det Almenmedicinske Kvalitetsprojekt. Afrappotering fra DAK-O. Det Centrale Kvalitets- og Informatikudvalg for almen praksis; 2006.
  3. Kronisk sygdom. Patient, sundhedsvæsen og samfund. Sundhedsstyrelsen; 2005.
  4. Andersen JS, Frølich 'A, Rytter L, Snorgaard O, Brix P. Kvalitetsprisen 2007 - Artikel 1. Bedre forløb for patienter med kroniske sygdomme - ved hjælp af tværsektoriel risikostratificering. Dansk Selskab for Kvalitet i Sundhedssektoren. DSKS-nyt 4 2006;4-7.
  5. Chronic obstructive pulmonary disease - management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Clinical Excellence http://www.nice.org.uk/page.aspx?o=cg012niceguideline. 2004 Feb.
  6. KOL - Kronisk Obstruktiv Lungesygdom: Anbefalinger for tidlig opsporing, opfølgning, behandling og rehabilitering. København: Sundhedsstyrelsen; 2007.
  7. Kjellberg J, Sørensen J, Hansen J, Andersen S, Avnstrøm L, Borgstrøm L. Almen praksis som koordinator - en international belysning. DSI rapport 2007;Dansk Sundhedsinstitut. København.
  8. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25;1(6077):1645-8.
  9. Standards for the diagnosis and Management of patients with COPD. American Thoracic Society and European Respiratory Society; 2004.
  10. Halpin D. NICE guidance for COPD. A further step in the process of developing better service and standards of care for the patients with COPD. Thorax 2004 Mar;59(3):181-2.
  11. Lokke A, Lange P, Vestbo J, Fabricius PG. Udvikling af kronisk obstruktiv lungesygdom -25-ars-opfolgningsstudie af baggrundsbefolkning--sekundaerpublikation. Ugeskr Laeger 2006 Dec 11;168(50):4422-4.
  12. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003 Jan;21(1):68-73.
  13. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ, Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999 Mar;115(3):635-41.
  14. Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar 4;350(10):1005-12.
  15. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002 May;121(5):1434-40.
  16. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004;(4):CD000165.
  17. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005;(2):CD001007.
  18. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar 4;340(9):685-91.
  19. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987 May;135(5):1069-74.
  20. Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004 Jun;59(6):471-6.
  21. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004 Jun;23(6):832-40.
  22. Oostenbrink JB, Rutten-van Molken MP, Al MJ, van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004 Feb;23(2):241-9.
  23. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999 Apr;115(4):957-65.
  24. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Sep 1;164(5):778-84.
  25. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13;320(7245):1297-303.
  26. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 Oct 15;166(8):1084-91.
  27. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003 Feb 8;361(9356):449-56.
  28. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003 Jan;21(1):74-81.
  29. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22;356(8):775-89.
  30. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988 Jan;1(1):22-6.
  31. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985 Jul;67(1):56-64.
  32. Decramer M, de B, V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1958-64.
  33. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994 Jul;150(1):11-6.
  34. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999 Oct;160(4):1248-53.
  35. Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999 Jan;13(1):125-32.
  36. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000 Jan 29;355(9201):362-8.
  37. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980 Sep;93(3):391-8.
  38. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981 Mar 28;1(8222):681-6.
  39. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995 Sep 14;333(11):710-4.
  40. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005 Sep 6;143(5):317-26.
  41. Eriksen N, Hansen EF, Munch EP, Rasmussen FV, Vestbo J. Kronisk obstruktiv lungesygdom. Indlaeggelse, forlob og prognose. Ugeskr Laeger 2003 Sep 8;165(37):3499-502.
  42. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999 Aug 7;354(9177):456-60.
  43. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999 Jun 24;340(25):1941-7.
  44. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987 Feb;106(2):196-204.
  45. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998 Apr;92(4):664-7.
  46. Weis N, Almdal T. C-reactive protein--can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med 2006 Mar;17(2):88-91.
  47. Pedersen SS, Gahrn-Hansen B. Antibiotikavejledning til almen praksis. www.irf.dk
  48. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003 Jul;58(7):589-93.
  49. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004 May;23(5):698-702.
  50. Connors AF, Jr., Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):959-67.
  51. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2005 update. NHL/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2005.
  52. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun;23(6):932-46.
  53. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer 2005 Feb 14;92(3):426-9.
  54. Juel K. Betydning af tobak, stort alkoholforbrug og stofmisbrug pa dodeligheden i Danmark. Udviklingen gennem 25 ar, 1973-1997. Ugeskr Laeger 2001 Aug 6;163(32):4190-5.
  55. Peto R, Lopez AD, Boreham J, Thun M, Heath C, Jr., Doll R. Mortality from smoking worldwide. Br Med Bull 1996 Jan;52(1):12-21.
  56. Kræftens Bekæmpelse. www.cancer.dk/tobak. 2006. Ref Type: Pamphlet
  57. Hansen NS. Tobakkens Biologi. København: Tobaksskaderådet; 2004.
  58. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991 Sep;86(9):1119-27.
  59. Røkeavvænning i Primærtjenesten. Oslo: Social- og Helsedirektoratet; 2004.
  60. Fiore MC, Bailey WC, Cohen SJ. Treating Tobacco Use and Dependence. Clinical Practice Guideline no 18 AHCPR Pub. No 96-0692. Rockvill MD:USDHHS Public Health Service; 2000.
  61. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000146.
  62. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000 Apr;59(4):1007-24.
  63. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998 Oct 12;158(18):2035-9.
  64. Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004 Nov 8;164(20):2229-33.
  65. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005 Oct 24;165(19):2286-92.
  66. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5;296(1):47-55.
  67. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5;296(1):56-63.
  68. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5;296(1):64-71.
  69. Scientific Discussion, EMEA. 2006. http://www.emea.europa.eu/humandocs/Humans/EPAR/champix/champix.htm. Ref Type: Pamphlet
  70. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006 Jun 15;173(12):1390-413.
  71. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Dec;160(6):1856-61.
  72. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 Jun;157(6 Pt 1):1791-7.
  73. KOL Rehabilitering. Danske Regioner Hovedstaden 2007 Aug.
  74. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review. Nord J Psychiatry 2004;58(1):65-70.
  75. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003 Jan;114(1):10-4.
  76. Inhalationssteroider og risiko for osteoporose. www.irf.dk.
  77. Roberts CM, Bugler JR, Melchor R, Hetzel MR, Spiro SG. Value of pulse oximetry in screening for long-term oxygen therapy requirement. Eur Respir J 1993 Apr;6(4):559-62.
  78. Iltbehandling i hjemmet. Dansk Lungemedicinsk Selskabs Kliniske retningslinjer. Dansk Lungemedicinsk Selskab 2006;www.lungemedicin.dk.
  79. Zielinski J. Effects of long-term oxygen therapy in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 1999 Mar;5(2):81-7.
  80. Balter MS, Daniak N, Chapman KR, Sorba SA, Rebuck AS. Erythropoietin response to acute hypoxemia in patients with chronic pulmonary disease. Chest 1992 Aug;102(2):482-5.
  81. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002 Aug;20(2):306-12.
  82. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J 2002 Jul;20(1):38-42.
  83. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995 Nov;5(4):717-34.
  84. Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998 Mar;157(3 Pt 1):715-22.
  85. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;(4):CD002733.
  86. EPI-NYT uge 42. http://www.ssi.dk/sw3022.asp. Statens Serum Institut; 2002.
  87. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003 May 22;348(21):2059-73.
  88. Wood DE, McKenna RJ, Jr., Yusen RD, Sterman DH, Ost DE, Springmeyer SC, et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thorac Cardiovasc Surg 2007 Jan;133(1):65-73.
  89. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998 Jan 3;351(9095):24-7.
  90. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998 Oct 15;66(7):951-6.
  91. Halliwell J, Mulcahy P, Buetow S, Bray Y, Coster G, Osman LM. GP discussion of prognosis with patients with severe chronic obstructive pulmonary disease: a qualitative study. Br J Gen Pract 2004 Dec;54(509):904-8.
  92. Murray SA, Pinnock H, Sheikh A. Palliative care for people with COPD: we need to meet the challenge. Prim Care Respir J 2006 Dec;15(6):362-4.
  93. Ziebell A, Buchwald D, Bjerrum L, Hald K, Leikersfeldt G, Møller N, et al. Palliation i primærsektoren. København: Dansk Selskab for Almen Medicin; 2004.
  94. Elkington H, White P, ddington-Hall J, Higgs R, Pettinari C. The last year of life of COPD: a qualitative study of symptoms and services. Respir Med 2004 May;98(5):439-45.
  95. Robson AG, Hartung TK, Innes JA. Laboratory assessment of fitness to fly in patients with lung disease: a practical approach. Eur Respir J 2000 Aug;16(2):214-9.
  96. Lungefunktionsstandard - Spirometri og Peakflow. Dansk Lungemedicinsk Selskab 2007.
  97. Lange P, Brøndum E, Phanareth K, Ringbaek TJ. Praktisk vejledning i fysisk træning af patienter med kronisk obstruktiv lungesygdom (KOL). Dansk Lungemedicinsk Selskab 2003.
  98. Netværk af forebyggende sygehuse i Danmark. Rehabilitering af kronisk obstruktiv lungesygdom - fakta, definitioner og anbefalinger. København 2003.
  99. Jones RC, Hyland ME, Hanney K, Erwin J. A qualitative study of compliance with medication and lifestyle modification in Chronic Obstructive Pulmonary Disease (COPD). Prim Care Respir J 2004 Sep;13(3):149-54.
  100. Hyland ME, Jones RC, Hanney K. The information needs of COPD patients why we developed the LINQ. The Airways Journal 2005;142-5.

 
DSAM, Øster Farimagsgade 5, Postboks 2099, 1014 København K - T: 3532 6590 - F: 3532 6591 - E: dsam@dsam.dk
Dudal Webdesign